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Introduction
Estrogen receptor (ER)-α is a member of the nuclear receptor
family of transcription factors. It is regulated not only by
binding to its ligand but also through interaction with co-
regulators that can either enhance (coactivators) or repress
(corepressors) its transcriptional activity. ER-α regulates the
expression of a large number of genes, including components
of the signaling, cell cycle, and anti-apoptosis pathways. A
great deal of work in this area has increased our
understanding of the role of ER-α in activation of genes; we
now know that binding of estrogen to ER-α results in
repositioning of helix 12 that allows recruitment of
coactivators and thus activation of transcription. However,
recent gene expression profiling by a number of groups using
different model systems has revealed that the majority of
estrogen-regulated genes are repressed rather than
activated. This has been shown in cells cultured in vitro but
also  in vivo, where estrogen treatment resulted in down-
regulation of a significant number of target genes. This
repression was lost in ER-α-knockout mice [1], confirming
that repression requires ER-α. Although estrogen-mediated
repression of genes has received little attention in the past, it
is likely to be critical for the role of ER-α in both normal and
disease processes. Herein we discuss some important
studies on repression by ER-α and try to highlight the most
burning (and partially controversial) questions.
Evidence for estrogen-mediated repression
of genes
There are a handful of studies that report estrogen-mediated
repression of genes, with some of them also addressing
potential mechanisms. For example, the ErbB2 proto-
oncogene is repressed by estrogen [2]. This repression
seems to result from competition between estrogen-bound
ER-α and another transcription factor (most likely activator
protein [AP]-2) for the coactivator steroid receptor
coactivator (SRC)-1, because overexpression of SRC-1, but
not SRC-2 or SRC-3, relieves repression of ErbB2. This
gives rise to the question of whether estrogen-mediated
repression really involves ‘classical’ repression, or merely
represents a loss of basal transcription caused by squelching
(i.e. competition for a limited pool of coactivators) or simple
displacement of coactivators.
There is some evidence that corepressors can play a role in
estrogen-mediated repression of genes. Overexpression of
the corepressors SMRT (silencing mediator for retinoid and
thyroid hormone receptors) and SAFB1 (scaffold attachment
factor B1) enhanced repression of folate receptor-α [3] and
E-cadherin [4], respectively. In contrast, none of the ER-α
coactivators tested (including SRC family members) affected
the repression of folate receptor-α by estrogen [3].
Interestingly, depletion of the corepressor DP97 attenuated
the repression of ErbB2 [5]. These data suggest that
corepressors are involved in repression, but is this really an
active recruitment of corepressors to the promoters of target
genes? Clearly, interaction of corepressors with ER-α in the
presence of estrogen does not fit the classical model in
which estrogen-bound ER-α interacts with coactivators,
whereas antiestrogen-bound ER-α preferentially interacts
with corepressors. However, based on a few studies showing
that some corepressors can bind ER-α in the presence of
estrogen and that coactivators and corepressors coexist in
complexes, it might be timely to revisit this model.
Another open question is whether nonclassical ER-α
pathways are involved in repression, just as described for
estrogen-mediated induction of genes. Does ER-α have to be
bound to estrogen response elements, or can it bind indirectly
via interaction with other transcription factors such as Sp1,
AP1, nuclear factor-κB, or CAAT-enhancer-binding protein-β?
Some studies have shown that the ER-α DNA-binding domain
(DBD) is necessary for the repression of certain genes
whereas for others it is not required. For example, mutation of
the ER-α DBD did not affect the repression of ErbB2,
whereas repression of the interleukin-6 promoter was
abolished [6]. Thus, repression of at least some genes seems
not to require direct binding of ER-α to promoter DNA.
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Finally, it may be that the homolog ER-β also plays a role in
estrogen-mediated repression of genes. This question has
not been addressed; however, some findings, such as the
interaction between estrogen-bound ER-β and corepressors,
favor such an involvement [7].
Conclusion
There is little doubt that estrogen treatment can result not
only in activation but also in repression of genes. Although
the mechanism of estrogen-mediated repression is largely
unknown, it is unlikely to be the same for all genes and may
depend on many factors such as the gene promoter and cell
context.
One of the critical questions is whether estrogen-bound ER-α
can, directly or indirectly, actively recruit corepressors to the
promoters of certain target genes to repress transcription.
Ultimately, however, the most important question pertains to
the biological relevance of estrogen-mediated repression; are
repressed genes critical targets of ER-α that need to be
turned off (or downregulated) for efficient ER-α activity? For
example, is estrogen-mediated repression of tumor
suppressor or apoptosis genes critical for breast cancer
development and progression? Ongoing studies in a number
of laboratories are expected to shed some light on this
exciting area in the near future.
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